Dermacyd Delicata Breeze - Photo Evaluation
Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze.
1 other identifier
interventional
28
1 country
1
Brief Summary
The purpose of this study is to prove the absence of photo irritation and photo sensitivity potential of the product Dermacyd Breeze.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3 healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 23, 2008
CompletedFirst Posted
Study publicly available on registry
April 29, 2008
CompletedFebruary 10, 2009
February 1, 2009
1 month
April 23, 2008
February 9, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.
5 weeks
Interventions
Eligibility Criteria
You may qualify if:
- Phototype Skin II and III
- Integral skin test in the region
You may not qualify if:
- Lactation or gestation
- Use of Antiinflammatory and/or immunosuppression drugs 15 days before the selection
- Diseases which can cause immunity decrease, such as HIV, diabetes
- Use of drug photosensitizer
- History of sensitivity or irritation for topic products
- Active cutaneous disease which can change the study results
- History or photodermatosis active
- Family or personal antecedent of cutaneous photoinduced neoplasias
- Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and keratoses actinium
- Intense solar exposure in the study area
- Use of new drugs or cosmetics during the study
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanofilead
Study Sites (1)
Sanofi-aventis administrative office
São Paulo, São Paulo, Brazil
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jaderson Lima
Sanofi-aventis administrative office Brazil
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 23, 2008
First Posted
April 29, 2008
Study Start
January 1, 2008
Primary Completion
February 1, 2008
Last Updated
February 10, 2009
Record last verified: 2009-02